MONROVIA, Calif.--(BUSINESS WIRE)--Jan. 18, 2006--Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Eli Lilly and Company a non-exclusive license to use Xencor’s ImmunoFilter technology to evaluate the potential immunogenicity of its therapeutic proteins. ImmunoFilter is a new predictive tool designed to enable Xencor and its partners to identify risk of future immunogenicity in antibody and other protein therapeutic candidates. Immunogenicity may reduce the therapeutic efficacy of a protein drug and may trigger potentially severe adverse events.
